DEF 14A: OptimizeRx Seeks Stockholder Approval for Equity Incentive Plan Expansion, Director Elections and Auditor Ratification Highlight Annual Meeting Agenda

OptimizeRx Corporation is holding its annual virtual meeting on June 5, 2024, to vote on director elections, executive compensation, an equity incentive plan amendment, and auditor ratification.

Summary

• OptimizeRx Corporation will hold its annual meeting of stockholders on Wednesday, June 5, 2024, at 10:00 a.m. EDT, via live audio webcast.
• Stockholders of record as of April 11, 2024, are eligible to vote.
• The agenda includes the election of six directors, an advisory vote on executive compensation, an amendment to the 2021 Equity Incentive Plan to increase the number of shares available by 1,950,000 to a total of 4,450,000, and the ratification of UHY LLP as the independent registered public accounting firm for the 2024 fiscal year.
• The board recommends voting 'FOR' all director nominees, the advisory vote on executive compensation, the equity incentive plan amendment, and the ratification of UHY LLP.
• The meeting will be a virtual format with no physical in-person meeting.

Sentiment

Score: 6

Explanation: The document is largely procedural, focusing on governance matters. The recommendation to vote 'FOR' all proposals suggests a positive outlook from the board, but the company's recent net losses temper the overall sentiment.

Positives

• The board is recommending a vote 'FOR' all proposals, indicating confidence in the company's direction.
• The proposed increase in shares for the equity incentive plan aims to attract, motivate, and retain key personnel.
• The company has a clawback policy in place to recover incentive-based compensation in certain circumstances.
• The company publicly shared its updated ESG report to highlight its efforts to deliver on the promise of stakeholder capitalism across 21 core metrics across four categories: Governance, Planet, People and Prosperity.

Negatives

• Gus Halas will not be standing for re-election, and his term will expire at the conclusion of the annual meeting.
• The company reported a net loss of $17,565,866 in 2023 and $11,438,440 in 2022.
• The company had to restate financials in the past leading to a clawback policy.

Risks

• Failure to secure stockholder approval for the equity incentive plan amendment could hinder the company's ability to attract and retain talent.
• An advisory vote against executive compensation could signal stockholder dissatisfaction and require the Compensation Committee to re-evaluate its approach.
• The company is subject to risks related to compensation policies and practices.

Future Outlook

The company expects the additional 1,950,000 shares under the amended equity plan to be sufficient for the next two to three fiscal years.

Industry Context

The document does not explicitly detail the broader industry trends, but the focus on digital healthcare technology and the use of equity compensation are common practices in the tech and healthcare sectors.

Comparison to Industry Standards

• The peer group for setting 2022 compensation decisions consisted of the following companies: CareCloud, Inc., iCAD, Inc., ShotSpotter, Inc., Castlight Health, Inc., Ideanomics, Inc., Simulations Plus, Inc., Computer Programs and Systems, Inc., Intelligent Systems Corporation, Smith Micro Software, Inc., Evolent Health, Inc., NantHealth, Inc., Tabula Rasa HealthCare, Inc., Health Catalyst, Inc., Phreesia, Inc., Vocera Communications, Inc., HealthStream, Inc.
• The updated peer groups median valuation is 1/3 of that of the prior peer group from 2021 utilized by the Compensation Committee ($225 million vs $606 million).
• The Compensation Committee believes that this group, when taken in aggregate, represents a reasonable market reference when determining the competitiveness of our pay programs for 2024.
• The 2024 Comparator Peer Group is: American Well Corporation, Domo, Inc., Phreesia, Inc., Arteris, Inc., Health Catalyst, Inc., Simulations Plus, Inc., Augmedix, Inc., HealthStream, Inc., Smith Micro Software, Inc., CareCloud, Inc., iCAD, Inc., SoundThinking, Inc., Computer Programs and Systems, Inc., Intellicheck, Inc., Viant Technology Inc., CoreCard Corporation, Kaltura, Inc.

Management Changes

Corporate Governance

Legal Proceedings

• On January 29, 2018, FINRA accepted a Letter of Acceptance, Waiver and Consent (the Consent) submitted by William Febbo.
• On September 28, 2018, the Securities and Exchange Commission (SEC) entered an Administrative Order consensually resolving an investigation into forward-looking financial goals and related disclosures by Mr. Wassons former employer, Walgreen Co. (Walgreens).

Related Party Transactions

• James Lang, one of our Board Members, is the Chief Executive Officer of EVERSANA, a leading provider of global commercialization services to the life science industry.
• OptimizeRx has entered into a Reseller Agreement with EVERSANA whereby EVERSANA may offer OptimizeRx solutions to its life sciences customers from which we generate revenue.
• During the years ended December 31, 2023 and December 31, 2022, respectively, we recognized $335,897 and $401,972 in revenue from OptimizeRx solutions sold by EVERSANA to its life sciences customers.

Stakeholder Impact

• Approval of the equity incentive plan amendment could positively impact employees and executives through equity-based compensation.
• The advisory vote on executive compensation allows stockholders to express their views on executive pay.
• The ratification of the independent auditor ensures the integrity of the company's financial reporting.

Next Steps

• Stockholders to vote on the proposals outlined in the proxy statement.
• The company to hold its annual meeting on June 5, 2024.
• The company to implement the approved proposals.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Equity Incentive Plan, Director Election, Executive Compensation, UHY LLP, Corporate Governance, Stockholders